The first two authors contributed equally to this work.
Potent hepatitis B surface antigen response to treatment of hepatitis-B-e-antigen-positive chronic hepatitis B with α-interferon plus a nucleos(t)ide analog
Article first published online: 21 FEB 2012
© 2011 Journal of Gastroenterology and Hepatology Foundation and Blackwell Publishing Asia Pty Ltd
Journal of Gastroenterology and Hepatology
Volume 27, Issue 3, pages 481–486, March 2012
How to Cite
Chen, X., Cao, Z., Liu, Y., Zhang, H., Zhang, Y., Ma, L., Jin, Y., Yu, H., Ma, B., Zheng, Y. and Wu, H. (2012), Potent hepatitis B surface antigen response to treatment of hepatitis-B-e-antigen-positive chronic hepatitis B with α-interferon plus a nucleos(t)ide analog. Journal of Gastroenterology and Hepatology, 27: 481–486. doi: 10.1111/j.1440-1746.2011.06970.x
- Issue published online: 21 FEB 2012
- Article first published online: 21 FEB 2012
- Accepted manuscript online: 18 NOV 2011 01:50PM EST
- Accepted for publication 23 October 2011.
- chronic hepatitis B;
- combination treatment;
- hepatitis B surface antigen seroconversion
Background and Aim: Hepatitis B surface antigen (HBsAg) clearance is the closest cure outcome in hepatitis B. The goal of this study was to investigate clinical features in chronic hepatitis B patients achieving seroconversion of HBsAg after treatment with α-interferon (IFN-α) and a nucleos(t)ide analog.
Methods: This retrospective study enrolled 38 chronic hepatitis B patients treated with IFN-α plus a nucleos(t)ide analog who achieved HBsAg seroconversion during the period from June 2001 to May 2009. Clinical and laboratory data of the patients were collected before and after treatment every 3 months. All patients with HBsAg seroconversion in this study were followed up for at least 12 months post-treatment.
Results: A total of 38 out of 142 patients achieved HBsAg seroconversion after treatment with IFN-α and a nucleos(t)tide analog for a prolonged period of time (medium 31 months). The median time to hepatitis B e antigen seroconversion and to HBsAg seroconversion was 19.5 months (range 3–60 months) and 25.5 months (range 9–63 months), respectively. Thirty-six patients (95%) sustained HBsAg seroconversion during the post-treatment follow up. Three different HBsAg response patterns were observed with classical model accounting for 57.9% (22/38 cases), simultaneous transition mode accounting for 23.7% (9/38 cases), and HBsAg prior transition model accounting for 18.4% (7/38 cases).
Conclusions: Extended treatment with IFN-α in combination with a nucleos(t)ide analog in patients with hepatitis-B-e-antigen-positive appears to be a promising approach for achieving a high rate of HBsAg clearance—the closest outcome to cure.